Short answer
Johnson & Johnson (JNJ) filed its Q1 2026 10-Q quarterly report on Apr 22, 2026 for the quarter ended Mar 29, 2026. Quarterly revenue was $24.1B (up 9.9% year over year) with net income of $5.2B.
Q1 2026 key financials · XBRL
- Revenue
- $24.1B
- +9.9% YoY
- Net income
- $5.2B
- −52.4% YoY
- Gross margin
- 66.3%
- EPS (diluted)
- $2.14
- −52.9% YoY
Source: XBRL data from the Johnson & Johnson (JNJ) Q1 2026 10-Q on SEC EDGAR. USD.
Johnson & Johnson Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $24.1B, up 9.9% YoY from $21.9B
- Earnings-before-tax margin 24.9% vs 62.3% YoY, reflecting $7.0B prior-year talc reserve reversal
- Best segment Innovative Medicine sales $15.4B, up 11.2%; worst segment MedTech margin 14.3% vs 17.7%
- Cash $21.7B, up $2.0B; operating cash flow $2.5B, dividends $3.1B, buybacks $4.0B
- Headwinds: STELARA operational decline 61.7%; expected SIMPONI and OPSUMIT biosimilar competition in 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Johnson & Johnson quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.